Levigress 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. This agent is commonly prescribed as adjunctive therapy in adults and pediatric patients over four years of age. Levigress 500 is well-absorbed orally with rapid onset of action and exhibits linear pharmacokinetics, allowing for flexible dosing regimens. It is generally well-tolerated; however, patients may experience side effects such as somnolence, dizziness, headache, and behavioral changes including irritability or mood swings. Dose adjustments may be necessary in patients with renal impairment to prevent accumulation and toxicity. Levigress should be used under strict medical supervision, with regular monitoring for efficacy and adverse effects. Abrupt discontinuation is not recommended due to the risk of increased seizure frequency. This medication is contraindicated in individuals with known hypersensitivity to Levetiracetam or any of its excipients. Levigress 500 Tablet provides an effective therapeutic option for seizure control, improving quality of life in patients with epilepsy.